NCT07798700 Biofluid Research on Age-Related or Inherited Neurodegeneration
| NCT ID | NCT07798700 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Frontotemporal Degeneration (FTD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-12-12 |
| Primary Completion | 2070-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-12-12 with a primary completion date of 2070-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions, or their family members who may or may not be at risk for similar conditions. This study will continue to further expand research into the molecular and genetic basis of these diseases and their risk factors.
Eligibility Criteria
Inclusion Criteria: 1. People with a clinical diagnosis of a neurodegenerative disease including, but not limited to Alzheimer's disease (AD), Parkinson's disease (PD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), primary progressive aphasia (PPA), limbic-predominant age-related TDP-43 encephalopathy (LATE), corticobasal syndrome (CBS), posterior cortical atrophy (PCA), primary lateral sclerosis (PLS), primary muscular atrophy (PMA), or individuals with a suspected neurodegenerative dementia and/or movement disorder of unknown etiology will be considered for enrollment 2. Family Members of individuals who meet the criteria of group 1, who are people who may or may not be at risk for a similar neurodegenerative disease, who may or may not be symptomatic, and who may or may not have known or unknown genetic risk. 3. People with no known neurological disease who will provide control data. Exclusion Criteria: 1. Anyone who is under the age of 18. 2. Anyone with a condition or in a situation which, in the investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological, and other medical conditions (such as cardiac, neurosurgical, infectious conditions).
Contact & Investigator
Corey McMillan, PhD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT07798700 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Frontotemporal Degeneration (FTD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07798700 currently recruiting?
Yes, NCT07798700 is actively recruiting participants. Contact the research team at cara.joyce@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07798700 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07798700 clinical trial?
NCT07798700 is sponsored by University of Pennsylvania. The principal investigator is Corey McMillan, PhD at University of Pennsylvania. The trial plans to enroll 1,000 participants.